Literature DB >> 7658061

Recombinant bacille Calmette-Guérin priming against measles.

G J Fennelly1, J L Flynn, V ter Meulen, U G Liebert, B R Bloom.   

Abstract

Live attenuated measles virus (MV) vaccines are ineffective in young infants because of neutralization by maternal antibody. An immunization strategy that may permit priming for T cell memory for MV in infants at or shortly after birth uses recombinant bacille Calmette-Guérin expressing the full-length MV nucleocapsid (N) protein (rBCG::N). C3H/He mice immunized with rBCG::N developed T cell responses and ELISA antibodies to the N protein and low levels of neutralizing antibody after intracranial infection with MV strain CAM/R40. There was considerable reduction in the virus titer recovered from brain homogenates, a decrease in the incidence and severity of histologic encephalitis, and a decrease in mortality in rBCG::N-printed C3H/He mice compared with control mice. Given the limitations of existing live attenuated MV vaccines, these results encourage the further testing of rBCG::N vaccines in primate models.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658061     DOI: 10.1093/infdis/172.3.698

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection.

Authors:  E Martin; J A Triccas; A T Kamath; N Winter; W J Britton
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.

Authors:  Mark J Cayabyab; Avi-Hai Hovav; Tsungda Hsu; Georgia R Krivulka; Michelle A Lifton; Darci A Gorgone; Glenn J Fennelly; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 3.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

4.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

5.  Genetic control of antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen.

Authors:  M Lagranderie; R Lo-Man; E Dériaud; B Gicquel; M Gheorghiu; C Leclerc
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Authors:  Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

7.  Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.

Authors:  Mark J Cayabyab; Birgit Korioth-Schmitz; Yue Sun; Angela Carville; Harikrishnan Balachandran; Ayako Miura; Kevin R Carlson; Adam P Buzby; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Genetic alteration of Mycobacterium smegmatis to improve mycobacterium-mediated transfer of plasmid DNA into mammalian cells and DNA immunization.

Authors:  Yongkai Mo; Natalie M Quanquin; William H Vecino; Uma Devi Ranganathan; Lydia Tesfa; William Bourn; Keith M Derbyshire; Norman L Letvin; William R Jacobs; Glenn J Fennelly
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

9.  Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.

Authors:  Uma Devi K Ranganathan; Michelle H Larsen; John Kim; Steven A Porcelli; William R Jacobs; Glenn J Fennelly
Journal:  Vaccine       Date:  2009-10-04       Impact factor: 3.641

10.  Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.

Authors:  Rosamund Chapman; Enid Shephard; Helen Stutz; Nicola Douglass; Vasan Sambandamurthy; Irene Garcia; Bernhard Ryffel; William Jacobs; Anna-Lise Williamson
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.